Roles of spectral dual-layer CT, D-dimer concentration, and COVID-19 pneumonia in diagnosis of pulmonary embolism.

Eur J Radiol Open

Department of Radiology and Nuclear Medicine, Faculty of Medicine, University Hospital Brno, Masaryk University, Jihlavská 340/20, Brno 625 00, Czech Republic.

Published: June 2024


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Purpose: To demonstrate advantages of spectral dual-layer computed tomography (CT) in diagnosing pulmonary embolism (PE). To compare D-dimer values in patients with PE and concomitant COVID-19 pneumonia to those in patients without PE and COVID-19 pneumonia. To compare D-dimer values in cases of minor versus extensive PE.

Methods: A monocentric retrospective study of 1500 CT pulmonary angiographies (CTPAs). Three groups of 500 consecutive examinations: 1) using conventional multidetector CT (CTC), 2) using spectral dual-layer CT (CTS), and 3) of COVID-19 pneumonia patients using spectral dual-layer CT (COV). Only patients with known D-dimer levels were enrolled in the study.

Results: Prevalence of inconclusive PE findings differed significantly between CTS and CTC (0.8 % vs. 5.4 %, < 0.001). In all groups, D-dimer levels were significantly higher in PE positive patients than in patients without PE (CTC, 8.04 vs. 3.05 mg/L; CTS, 6.92 vs. 2.57 mg/L; COV, 10.26 vs. 2.72 mg/L, < 0.001). There were also statistically significant differences in D-dimer values between minor and extensive PE in the groups negative for COVID-19 (CTC, 5.16 vs. 8.98 mg/L; CTS 3.52 vs. 9.27 mg/L, < 0.001). The lowest recorded D-dimer value for proven PE in patients with COVID-19 pneumonia was 1.19 mg/L.

Conclusion: CTPAs using spectral dual-layer CT reduce the number of inconclusive PE findings. Plasma D-dimer concentration increases with extent of PE. Cut-off value of D-dimer with 100 % sensitivity for patients with COVID-19 pneumonia could be doubled to 1.0 mg/L. This threshold would have saved 110 (22 %) examinations in our cohort.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11179566PMC
http://dx.doi.org/10.1016/j.ejro.2024.100575DOI Listing

Publication Analysis

Top Keywords

covid-19 pneumonia
24
spectral dual-layer
20
d-dimer values
12
patients covid-19
12
d-dimer
9
d-dimer concentration
8
pulmonary embolism
8
compare d-dimer
8
patients
8
pneumonia patients
8

Similar Publications

Since the first decentralized clinical trial (DCT) was conducted in 2011, there has been an increased usage of DCT due to its benefits of patient-centricity and generalizability of findings. This trend was further expedited by the global COVID-19 pandemic. We identified 23 case studies across various therapeutic areas and grouped them into different categories according to their purposes-by necessity, for operational benefits, to address unique research questions, to validate innovative digital endpoints, or to validate decentralization as a clinical research platform.

View Article and Find Full Text PDF

Objective: Although existing evidence suggests a potential link between dementia and adverse outcomes in patients with COVID-19, a definitive relationship is uncertain. This study aimed to evaluate the impact of dementia on in-hospital outcomes of patients in the presence of COVID-19.

Methods: The US Nationwide Inpatient Sample (NIS) was searched for patients 65 years or older hospitalised for COVID-19 in 2020.

View Article and Find Full Text PDF

Background: Dyspnea is a common clinical symptom and cause of outpatient and inpatient presentations to the clinic. Diagnostic and therapeutic challenges appear, when additional diseases appear that are themselves associated with subjectively perceptible dyspnea. We report on a young woman with orthopnea as a trigger of a diagnostic cascade of various diseases.

View Article and Find Full Text PDF

Introduction: The COVID-19 pandemic had significant global public health consequences, affecting over 200 countries and regions by 2020. The development and efficacy of specific vaccines, such as the mRNA-1273 (Spikevax) vaccine developed by Moderna Inc., have substantially reduced the impact of the pandemic and mitigated its consequences.

View Article and Find Full Text PDF

Respiratory diseases pose a significant global health burden, prompting the exploration of novel therapeutic strategies. This narrative review consolidates existing knowledge and critically examines the evolving role of medical gases, ozone, argon, and nitric oxide (NO), in respiratory medicine. Based on recent literature, it highlights how these gases, originally used for their physicochemical properties, have now undergone a "functional crossover," revealing their broad therapeutic potential.

View Article and Find Full Text PDF